MAIA Biotechnology Announces FDA Fast Track For First-in-Class Telomere-Targeting Drug In NSCLC; Latest Data In Pivotal Phase 2 THIO-101 Clinical Trial Shows Median Overall Survival Of 17.8 Months
Benzinga Newsdesk 1 year ago
BiotechNewsFDAGeneral
Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment marketLatest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of 17.8 monthsMAIA
Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment market
Latest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of 17.8 months
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC). Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor.
Ateganosine is a first-in-class small molecule that compromises telomere structure and function in cancer cells, leading to rapid tumor cell elimination and specific immune memory. Through telomerase-mediated action, ateganosine reverses intrinsic or acquired resistance to immune checkpoint inhibitors (ICIs).